We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

12 hedge funds and large institutions have $1.13M invested in Viking Therapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

49% more capital invested

Capital invested by funds: $758K → $1.13M (+$368K)

0.08% more ownership

Funds ownership: 3.16% → 3.23% (+0.08%)

0% more funds holding

Funds holding: 12 → 12 (0)

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$143K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$84.5K
3
SKK
Shepherd Kaplan Krochuk
Massachusetts
+$12.6K
4
UBS Group
UBS Group
Switzerland
+$6.3K
5
AIM
Acrospire Investment Management
Illinois
+$2.62K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$35K
2
Morgan Stanley
Morgan Stanley
New York
-$21.3K

VKTX Hedge Fund Activity: Q1 2017 in Review

12 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2017, worth a combined $1.13M — up 49% from $758K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VKTX positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $143K. The largest seller was Goldman Sachs, exiting entirely with an estimated $35K sold.

  • 12 institutional investors held Viking Therapeutics (VKTX) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $1.13M of Viking Therapeutics stock for Q1 2017, up 49% quarter-over-quarter.
  • 2 funds opened new Viking Therapeutics positions in Q1 2017 and 1 closed out, a net change of +1 holder.
  • The largest Viking Therapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $143K added.
  • The largest Viking Therapeutics seller in Q1 2017 was Goldman Sachs, an estimated $35K sold.

Based on aggregated 13F filings for Q1 2017.